Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?

Dermatol Ther. 2021 Sep;34(5):e15050. doi: 10.1111/dth.15050. Epub 2021 Jul 6.

Authors

Angelo Massimiliano D'Erme¹, Cristian Fidanzi², Agata Janowska², Giacomo Allegrini³, Cecilia Barbara³, Samanta Cupini³, Paolo Viacava⁴, Giovanni Bagnoni¹

Affiliations

¹ Melanoma and Skin Cancer Unit AVNO (Area Vasta Nord Ovest) and Unit of Dermatology, Livorno Hospital, Livorno, Italy.
² Unit of Dermatology, University of Pisa, Pisa, Italy.
³ Unit of Oncology, Livorno Hospital, Livorno, Italy.
⁴ Unit of Pathology, Livorno Hospital, Livorno, Italy.

PMID: 34212457
DOI: 10.1111/dth.15050

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Melanoma* / drug therapy
Prognosis
Psoriasis* / chemically induced
Psoriasis* / diagnosis
Psoriasis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab